The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Judge Margaret Seymour held a hearing to better understand the facts of the case before deciding whether it should go forward.
The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.
At its investor day presentation, the company will outline its strategy for accelerating growth and driving operational excellence.
Experts pointed out the lack of clarity in professional standards and regulations when it comes to dealing with genetic variation in patient care.
A high-profile, independent committee is considering the liability issues impacting labs as genetic testing increasingly becomes integrated into patient care.
Under the terms of the agreement, Q2 Solutions will develop companion diagnostics on Illumina's MiSeqDx instrument.
The firm said that business agreements with IBM, Ancestry, and others will help it stay on track in meeting commitments for the year.
The partnership provides oncology sequencing and cognitive analytics, and it offers a framework for employing Watson to explore a broader set of diagnostic opportunities.
The service provides broad access to information that may be critical for physicians in providing precision cancer treatments.
The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
The first Reproducibility Project: Cancer Biology papers show mixed results.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.